# Aminopterin in Treating Patients With Refractory Leukemia

> **NCT00003305** · PHASE2 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 75 (estimated)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** aminopterin
- **DRUG:** leucovorin calcium

## Key facts

- **NCT ID:** NCT00003305
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-07
- **Primary completion:** —
- **Final completion:** 2007-09
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2014-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003305, "Aminopterin in Treating Patients With Refractory Leukemia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00003305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*